Kyverna Therapeutics, Inc.
KYTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001994702
No open-market purchases or sales by Kyverna Therapeutics, Inc. insiders were filed in the last 90 days; 120 institutions reported holding it in 13F filings for Q2 2026, worth $335.1M in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Kyverna Therapeutics, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 88
- −2 vs. Q1 2024
- Shares held
- 31.9M
- +1.25M (+4.1%) vs. Q1 2024
- Total value
- $239.7M
- −$522.6M (−68.6%) vs. Q1 2024
- New holders
- 28
- 34 more added
- Sold out
- 30
- 12 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KYTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 120 | $335.1M |
| Q1 2026 | 111 | $300.5M |
| Q4 2025 | 99 | $320.8M |
| Q3 2025 | 75 | $136.1M |
| Q2 2025 | 79 | $71.2M |
| Q1 2025 | 87 | $49.8M |
| Q4 2024 | 88 | $108.0M |
| Q3 2024 | 94 | $138.3M |
| Q2 2024 | 88 | $239.7M |
| Q1 2024 | 90 | $762.3M |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Kyverna Therapeutics, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| ArrowMark Colorado Holdings LLC | 0 | $0 | 0.00% | −70,000−100.0% | Sold out |
| Point72 (DIFC) Ltd | 0 | $0 | 0.00% | −60,800−100.0% | Sold out |
| Hudson Bay Capital Management LP | 0 | $0 | 0.00% | −50,000−100.0% | Sold out |
| Paradigm Biocapital Advisors LP | 0 | $0 | 0.00% | −50,000−100.0% | Sold out |
| StemPoint Capital LP | 0 | $0 | 0.00% | −41,000−100.0% | Sold out |
| Laurion Capital Management LP | 0 | $0 | 0.00% | −37,500−100.0% | Sold out |
| Point72 Asset Management, L.P. | 0 | $0 | 0.00% | −20,900−100.0% | Sold out |
| Davidson Kempner Capital Management LP | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −16,721−100.0% | Sold out |
| Prudential Financial Inc | 0 | $0 | 0.00% | −11,500−100.0% | Sold out |
| Brevan Howard Capital Management LP | 0 | $0 | 0.00% | −11,435−100.0% | Sold out |
| Point72 Asia (Singapore) Pte. Ltd. | 0 | $0 | 0.00% | −10,133−100.0% | Sold out |
| Greenland Capital Management LP | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Diametric Capital, LP | 0 | $0 | 0.00% | −9,300−100.0% | Sold out |
| Tudor Investment Corp Et Al | 0 | $0 | 0.00% | −8,492−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −2,775−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −766−100.0% | Sold out |
| Macquarie Group Ltd | 0 | $0 | 0.00% | −950−100.0% | Sold out |